Medifast MED Accounts payable and other current liabilities (Note 11)
Accounts payable and other current liabilities (Note 11) at other companies
Other financials
Where this comes from
Reported directly by Medifast in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: Medifast’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medifast's accounts payable and other current liabilities (note 11).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medifast's accounts payable and other current liabilities (note 11)?
- Medifast (MED) reported accounts payable and other current liabilities (note 11) of $38.26M in Q1 2026.
- How has Medifast's accounts payable and other current liabilities (note 11) changed year-over-year?
- Medifast's accounts payable and other current liabilities (note 11) decreased by 26.2% year-over-year, from $51.82M to $38.26M.
- What is the long-term trend for Medifast's accounts payable and other current liabilities (note 11)?
- Over 5 years (2020 to 2025), Medifast's accounts payable and other current liabilities (note 11) has grown at a -18.7% compound annual growth rate (CAGR), from $107.68M to $38.36M.